Immunogenicity and safety of intradermal injection of reduced dose Inactivated Poliovirus vaccine (IPV) with a jet injector in healthy adults.

etherlands Vaccine Institute RIVM, formerly Nederland Vaccine, Institute (NVI)0 sites120 target enrollmentTBD

Conditionspoliomyelitis, polio, vaccination, vaccinatie, intradermal, intradermaal, jet injector, needle-free, naaldloos

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: poliomyelitis, polio, vaccination, vaccinatie, intradermal, intradermaal, jet injector, needle-free, naaldloos
Sponsor: etherlands Vaccine Institute RIVM, formerly Nederland Vaccine, Institute (NVI)
Enrollment: 120
Status: Completed
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

Registry

who.int

Start Date

TBD

End Date

TBD

Last Updated

2 years ago

Study Type

Interventional

Investigators

Sponsor

etherlands Vaccine Institute RIVM, formerly Nederland Vaccine, Institute (NVI)

Eligibility Criteria

Inclusion Criteria

•1\. Age ¡Ý 18 years;
•2\. Good health according to the investigator;

Exclusion Criteria

•1\. IPV booster dose after 10 years of age;
•2\. OPV dose;

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed

Phase 2

Immunogenicity and safety of intradermal injection of reduced dose Inactivated Poliovirus vaccine (IPV) with a jet injector in healthy adultsinfantile paralysispolio10047438

NL-OMON32437ederlands Vaccin Instituut120

Active, not recruiting

Not Applicable

Immunogenicity and safety of intradermal injection of reduced dose Inactivated Poliovirus vaccine (IPV) with a jet injector in healthy adults - Intradermal injection of reduced dose IPV in adults

EUCTR2009-015175-27-NLetherlands Vaccine Institute

Recruiting

Phase 4

Intradermal booster COVID-19 vaccinatioIntradermal mRNA-based vaccine following the 2-dose primary series of ChAdOx1 (AstraZeneca) can provide a sufficient level of immunity against SAR-CoV-2booster vaccine, third dose, SAR-CoV2, older adult

TCTR20220112002Faculty of Medicine Siriraj Hospital, Mahidol University210

Completed

Not Applicable

Immunogenicity and safety of an intradermal boost in healthy general population; preliminary study. (COVID-19)

TCTR20211004001faculty of medicine, Prince of songkla university240

Completed

Phase 3

The saftey and efficacy of intradermal injection of type A butulinum toxin in chemotherapy induced peripheral neuropathyChemotherapy induced neuropathy.

IRCT20200425047202N1Shahid Beheshti University of Medical Sciences40